South Wales, Nov. 21 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "RESILIOME" on Sept. 15. The details about the trademark application no. UK00004264177 published in the journal no. 2025/047 (Nov. 21).
With Mewburn Ellis LLP as representative, Alchemab Therapeutics Ltd filed the trademark application for the below mentioned good(s)/service(s).
Class 1 : Chemical preparations for scientific or research purposes, other than for medical use; antibodies for scientific or research purposes, other than for medical use; diagnostic preparations for scientific or research purposes, other than for medical use.
Class 5 : Pharmaceutical preparations; Medicines for human purposes; Pharmaceutical preparations incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes; pharmaceutical preparations incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; Chemical preparations for medical and pharmaceutical purposes incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; antibodies for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations involving the testing and identification of antibodies for medical purposes.
Class 9 : Downloadable software for the testing of antibodies; downloadable software for the identification of antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibody technology.
Class 42 : Scientific and technological services; research and development services; research and development services in the field of antibodies and antibody technology; drug development services; drug discovery services; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and antibody technology; antibody discovery and identification services; antibody discovery services for the purpose of drug discovery; research in the field of biomarkers; research and development in the field of pharmaceuticals; research and development in the field of diagnostic preparations; clinical research; clinical trials; development and testing of computing methods, algorithms and software in biotechnology and medical fields, including antibody technology; development and testing of computing methods, algorithms and software for the testing and identification of antibodies; development and testing of computing methods, algorithms and software relating to the development of pharmaceutical preparations incorporating antibodies and antibody technology; platforms as a service [PaaS] and software as a service [SaaS] in the field of medicine discovery; information, advisory and consultancy services in relation to all of the aforesaid.
Class 44 : Medical testing for diagnostic or treatment purposes; medical diagnostic services; medical analysis for diagnostic and treatment purposes; medical testing, analysis and diagnostic services in the field of antibodies and biomarkers; medical diagnostic services involving the testing of antibodies for medical purposes; analysis and identification of antibody data for medical and diagnostic purposes; information, advisory and consultancy services in relation to all of the aforesaid.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004264177
Disclaimer: Curated by HT Syndication.
